Want to see AZTR full AI Analyst Report?
AZTR Stock Chart & Stats
$0.30
-$0.02(-5.17%)
At close: 4:00 PM EST
$0.30
-$0.02(-5.17%)
Day’s Range― - ―
52-Week Range$0.10 - $1.74
Previous CloseN/A
Volume201.32K
Average Volume (3M)169.78K
Market Cap
$2.45M
Enterprise Value-$7.53M
Total Cash (Recent Filing)$10.05M
Total Debt (Recent Filing)$343.33K
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Aug 17, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.47
Shares Outstanding16,192,438
10 Day Avg. Volume152,326
30 Day Avg. Volume169,784
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.34
Price to Sales (P/S)0.00
P/FCF Ratio-0.11
Enterprise Value/Market Cap-3.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit22.11
Enterprise Value/Ebitda0.69
Forecast
1Y Price Target
$1.00Price Target Upside233.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.49
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Strain Library & AI PlatformA ~1,500‑strain library combined with AI/ML discovery tools creates a durable platform advantage: it enables faster candidate identification, reuse across multiple indications and product classes, and scalable R&D efficiencies that support long‑term pipeline breadth and partnership potential.
Strategic Shift To Nearer‑term Commercial PathwaysPivoting toward cosmetics (ATR‑COSF) and biotech tools narrows time to potential revenue and reduces binary clinical risk. Targeting 2027 commercialization/partnering horizons and licensing opportunities creates multiple durable commercialization pathways that can accelerate cash generation and external partnerships.
Improved Capitalization And Manageable LeverageRecent balance‑sheet improvements and modest debt relative to equity reduce immediate solvency pressure, giving the company runway to execute its strategic pivot. Manageable leverage supports financing flexibility for near‑term product optimization and partnership discussions without immediate distress.
Bears Say
Revenue Collapse And Inconsistent Commercial ScaleRevenue falling to zero in 2025 and TTM shows lack of established, recurring commercial traction. This structural inconsistency undermines sustainable cash generation, raises execution risk for commercialization plans, and means future growth relies heavily on successful pivots or partnerships.
Deteriorating Cash Generation And High BurnSignificantly worsening operating and free cash flow in the trailing twelve months indicates losses are translating into real cash drain. Persistent burn necessitates frequent financing, increases dilution risk, and constrains sustained investment in R&D, trials, and commercialization over the medium term.
Authorized Share Increase And Governance ShortfallsA large authorized share expansion and an adjourned annual meeting signal governance and dilution risk: the company has structural capacity to issue equity and showed weak shareholder engagement, both of which can enable dilution and reduce investor confidence over time.
Azitra Inc News
AZTR FAQ
What was Azitra Inc’s price range in the past 12 months?
Azitra Inc lowest stock price was $0.10 and its highest was $1.74 in the past 12 months.
What is Azitra Inc’s market cap?
Azitra Inc’s market cap is $2.45M.
When is Azitra Inc’s upcoming earnings report date?
Azitra Inc’s upcoming earnings report date is Aug 17, 2026 which is in 42 days.
How were Azitra Inc’s earnings last quarter?
Azitra Inc released its earnings results on May 13, 2026. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.01 by -$0.24.
Is Azitra Inc overvalued?
According to Wall Street analysts Azitra Inc’s price is currently Undervalued.
Does Azitra Inc pay dividends?
Azitra Inc does not currently pay dividends.
What is Azitra Inc’s EPS estimate?
Azitra Inc’s EPS estimate is -0.12.
How many shares outstanding does Azitra Inc have?
Azitra Inc has 16,192,438 shares outstanding.
What happened to Azitra Inc’s price movement after its last earnings report?
Azitra Inc reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.01. Following the earnings report the stock price went down -1.818%.
Which hedge fund is a major shareholder of Azitra Inc?
Currently, no hedge funds are holding shares in AZTR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Azitra Inc
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S. epidermidis strain, designed to alleviate the papulopustular rash commonly experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy. ATR-01: An engineered recombinant human filaggrin protein developed for the treatment of ichthyosis vulgaris, another dermatological ailment. Founded in 2014, Azitra, Inc. operates from its headquarters in Branford, Connecticut.
AZTR Stock 12 Month Forecast
Average Price Target
$1.00
▲(233.33% Upside)
Technical Analysis
Ownership Overview
27.62% Insiders
0.47% Mutual Funds
0.14% Other Institutional Investors
71.76% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---